Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Earnings Results, Beats Expectations By $0.24 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced its quarterly earnings data on Monday. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.24, FiscalAI reports.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock traded up $0.02 on Monday, hitting $1.74. The stock had a trading volume of 1,273,694 shares, compared to its average volume of 1,531,419. The business has a 50 day moving average of $2.74 and a 200 day moving average of $3.41. The stock has a market cap of $124.71 million, a price-to-earnings ratio of -0.89 and a beta of 1.91. Zentalis Pharmaceuticals has a 12-month low of $1.25 and a 12-month high of $6.95.

Insiders Place Their Bets

In other news, major shareholder Group Walters acquired 4,335,000 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the transaction, the insider owned 17,844,973 shares of the company’s stock, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.80% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “outperform” rating for the company. Jefferies Financial Group upgraded shares of Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Friday, October 2nd. Leerink Partners began coverage on shares of Zentalis Pharmaceuticals in a report on Monday, October 5th. They set an “outperform” rating and a $8.00 price objective for the company. Finally, Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.